, Blood, vol.111, pp.2962-2972, 2008.
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma, N. Engl. J. Med, vol.366, pp.1782-1791, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00852275
Lenalidomide after stem-cell transplantation for multiple myeloma, N. Engl. J. Med, vol.366, pp.1770-1781, 2012. ,
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis, J. Clin. Oncol, vol.35, pp.3279-3289, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01697539
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, pp.9-16, 2015. ,
Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat. Med, vol.20, pp.1472-1478, 2014. ,
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N. Engl. J. Med, vol.371, pp.2477-2487, 2014. ,
Age-related clonal hematopoiesis associated with adverse outcomes, N. Engl. J. Med, vol.371, pp.2488-2498, 2014. ,
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, pp.9-16, 2015. ,
New insights from studies of clonal hematopoiesis, Clin. Cancer Res, vol.24, pp.4633-4642, 2018. ,
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease, N. Engl. J. Med, vol.377, pp.111-121, 2017. ,
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood, vol.130, pp.742-752, 2017. ,
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults, Nat. Commun, vol.7, p.12484, 2016. ,
Prediction of acute myeloid leukaemia risk in healthy individuals, Nature, vol.559, pp.400-404, 2018. ,
Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat. Med, vol.24, pp.1015-1023, 2018. ,
Clonal hematopoiesis and risk of acute myeloid leukemia, Haematologica, vol.104, pp.2410-2417, 2019. ,
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature, vol.518, pp.552-555, 2015. ,
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, Cell Stem Cell, vol.21, p.4, 2017. ,
Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J. Clin. Oncol, vol.35, pp.1598-1605, 2017. ,
Preleukaemic clonal haemopoiesis and risk of therapyrelated myeloid neoplasms: a case-control study, Lancet Oncol, vol.18, pp.100-111, 2017. ,
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study, Lancet Oncol, vol.18, pp.112-121, 2017. ,
Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation, Leukemia, vol.32, pp.2020-2024, 2018. ,
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma, Blood, vol.132, pp.587-597, 2018. ,
Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma, J. Clin. Oncol, vol.33, pp.3911-3920, 2015. ,
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat. Commun, vol.5, p.2997, 2014. ,
Genomic landscape and chronological reconstruction of driver events in multiple myeloma, Nat. Commun, vol.10, p.3835, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02290176
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, vol.25, pp.91-101, 2014. ,
Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma, Bone Marrow Transplant, vol.51, pp.1143-1145, 2016. ,
Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma, J. Cancer Res Clin. Oncol, vol.135, pp.637-642, 2009. ,
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells, Blood, vol.132, pp.1095-1105, 2018. ,
PPM1D mutations drive clonal hematopoiesis in Rresponse to cytotoxic chemotherapy, Cell Stem Cell, vol.23, pp.700-713, 2018. ,
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies, Science, vol.365, pp.599-604, 2019. ,
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice, Science, vol.355, pp.842-847, 2017. ,
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide, Haematologica, vol.103, pp.143-149, 2018. ,
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression, J. Clin. Oncol, vol.29, pp.1971-1979, 2011. ,
Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma, N. Engl. J. Med, vol.376, pp.1311-1320, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01557406
Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial, J. Clin. Oncol, vol.37, pp.589-597, 2019. ,
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma, Cancer, vol.118, pp.1585-1592, 2012. ,
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma, Leuk. Lymphoma, vol.54, pp.1658-1664, 2013. ,
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis, Leukemia, vol.31, pp.1727-1734, 2017. ,
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, Nat. Commun, vol.8, p.1324, 2017. ,
Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer, Genome Res, vol.22, 1995. ,
TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data, Genome Res, vol.24, pp.1881-1893, 2014. ,
Initial genome sequencing and analysis of multiple myeloma, Nature, vol.471, pp.467-472, 2011. ,
A framework for variation discovery and genotyping using next-generation DNA sequencing data, Nat. Genet, vol.43, pp.491-498, 2011. ,
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat. Biotechnol, vol.31, pp.213-219, 2013. ,
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs, Bioinformatics, vol.28, pp.1811-1817, 2012. ,
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation, Nucleic Acids Res, vol.41, p.67, 2013. ,
Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, vol.505, pp.495-501, 2014. ,
Absolute quantification of somatic DNA alterations in human cancer, Nat. Biotechnol, vol.30, pp.413-421, 2012. ,
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, vol.20, pp.1297-1303, 2010. ,
The Ensembl variant effect predictor, Genome Biol, vol.17, p.122, 2016. ,
Oncotator: cancer variant annotation tool, Hum. Mutat, vol.36, pp.2423-2429, 2015. ,
Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data, Am. J. Hum. Genet, vol.91, pp.839-848, 2012. ,
The ExAC browser: displaying reference data information from over 60 000 exomes, Nucleic Acids Res, vol.45, pp.840-845, 2017. ,
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation, N. Engl. J. Med, vol.376, pp.536-547, 2017. ,
Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-291, 2016. ,
Integrative genomics viewer, Nat. Biotechnol, vol.29, pp.24-26, 2011. ,
Paired exome analysis of Barrett's esophagus and adenocarcinoma, Nat. Genet, vol.47, pp.1047-1055, 2015. ,
International staging system for multiple myeloma, J. Clin. Oncol, vol.23, pp.3412-3420, 2005. ,
Writing -Original Draft, and I.M.G. Competing interests The authors declare the following competing interests: M.B.: Dava Oncology: Honoraria. N.C.M.: OncoPep: Other: Board of director. K.C.A.: Gilead: Membership on an entity's ,
Oncopeptides: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research ,
, Research Funding
, Research Funding
Celgene: Research funding; Deerfield: Research funding; GRAIL: Consultancy; Exo Therapeutics: scientific advisory boards; Skyhawk Therapeutics: scientific advisory boards, Talaris Therapeutics: Consultancy; TScan Therapuetics ,
Celgene: Consultancy; Janssen: Consultancy; BMS: Consultancy; Takeda: Consultancy; GSK: Consultancy; Sanofi: Consultancy; Karyopharm: Consultancy; Abbvie: Consultancy; Cellectar: Consultancy; Genentech: Consultancy, receives research funds from IBM and Pharmacyclics and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig ,